Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm.

OBJECTIVE Dysfunctional attitudes are negatively biased assumptions and beliefs regarding oneself, the world, and the future. In healthy subjects, increasing serotonin (5-HT) agonism with a single dose of d-fenfluramine lowered dysfunctional attitudes. To investigate whether the converse, a low level of 5-HT agonism, could account for the higher levels of dysfunctional attitudes observed in patients with major depression or with self-injurious behavior, cortex 5-HT(2) receptor binding potential and dysfunctional attitudes were measured in patients with major depressive disorder, patients with a history of self-injurious behavior, and healthy comparison subjects (5-HT(2) receptor density increases during 5-HT depletion). METHOD Twenty-nine healthy subjects were recruited to evaluate the effect of d-fenfluramine or of clonidine (control condition) on dysfunctional attitudes. Dysfunctional attitudes were assessed with the Dysfunctional Attitude Scale 1 hour before and 1 hour after drug administration. In a second experiment, dysfunctional attitudes and 5-HT(2) binding potential were measured in 22 patients with a major depressive episode secondary to major depressive disorder, 18 patients with a history of self-injurious behavior occurring outside of a depressive episode, and another 29 age-matched healthy subjects. Cortex 5-HT(2) binding potential was measured with [(18)F]setoperone positron emission tomography. RESULTS In the first experiment, dysfunctional attitudes decreased after administration of d-fenfluramine. In the second experiment, in the depressed group, dysfunctional attitudes were positively associated with cortex 5-HT(2) binding potential, especially in Brodmann's area 9 (after adjustment for age). Depressed subjects with extremely dysfunctional attitudes had higher 5-HT(2) binding potential, compared to healthy subjects, particularly in Brodmann's area 9. CONCLUSIONS Low levels of 5-HT agonism in the brain cortex may explain the severely pessimistic, dysfunctional attitudes associated with major depression.

[1]  B. Barraclough,et al.  A Hundred Cases of Suicide: Clinical Aspects , 1974, British Journal of Psychiatry.

[2]  Karl J. Friston,et al.  Assessing the significance of focal activations using their spatial extent , 1994, Human brain mapping.

[3]  A. Peñalva,et al.  Depending on the stimulus, central serotoninergic activation by fenfluramine blocks or does not alter growth hormone secretion in man. , 1984, Neuroendocrinology.

[4]  B. A. van der Kolk,et al.  Trauma and the development of borderline personality disorder. , 1994, The Psychiatric clinics of North America.

[5]  KA Smith,et al.  Relapse of depression after rapid depletion of tryptophan , 1997, The Lancet.

[6]  H. Meltzer,et al.  Laterality and 3H-imipramine binding: Studies in the frontal cortex of normal controls and suicide victims , 1991, Biological Psychiatry.

[7]  P S Goldman-Rakic,et al.  5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C Crouzel,et al.  Synthesis, affinity and specificity of 18F-setoperone, a potential ligand for in-vivo imaging of cortical serotonin receptors. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[9]  Karl J. Friston,et al.  Spatial registration and normalization of images , 1995 .

[10]  V. Arango,et al.  Alterations in Monoamine Receptors in the Brain of Suicide Victims , 1992, Journal of clinical psychopharmacology.

[11]  B. Jacobs,et al.  Life‐span dendritic and spine changes in areas 10 and 18 of human cortex: A quantitative golgi study , 1997, The Journal of comparative neurology.

[12]  S. Kapur,et al.  Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. , 1999, The American journal of psychiatry.

[13]  D. McManus,et al.  Chronic administration of the antidepressants phenelzine, despiramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in rat brain , 1995, Cellular and Molecular Neurobiology.

[14]  G. Elmer,et al.  Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction. , 1998, Annals of the New York Academy of Sciences.

[15]  M. Palkovits,et al.  5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala , 1993, Brain Research.

[16]  Paul J. Harrison,et al.  β-blocker Binding to Human 5-HT1A Receptors in vivo and in vitro: Implications for Antidepressant Therapy , 2000, Neuropsychopharmacology.

[17]  H. Meltzer,et al.  Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. , 1989, The American journal of psychiatry.

[18]  C Crouzel,et al.  A Method for the In Vivo Investigation of the Serotonergic 5‐HT2 Receptors in the Human Cerebral Cortex Using Positron Emission Tomography and 18F‐Labeled Setoperone , 1990, Journal of neurochemistry.

[19]  M. Blais,et al.  A psychometric evaluation of the DSM-IV personality disorder criteria. , 1997, Journal of personality disorders.

[20]  M. Kleven,et al.  Depletion of 5-HT Disrupts Prepulse Inhibition in Rats: Dependence on the Magnitude of Depletion, and Reversal by a 5-HT Precursor , 2002, Neuropsychopharmacology.

[21]  V. Arango,et al.  Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. , 1990, Archives of general psychiatry.

[22]  Axel Bossuyt,et al.  SPECT imaging of serotonin2 receptors in depression , 1992, Psychiatry Research: Neuroimaging.

[23]  Alan A. Wilson,et al.  The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. , 2001, The American journal of psychiatry.

[24]  C Krogh,et al.  "Compendium of pharmaceuticals and specialties". , 1983, Canadian Medical Association journal.

[25]  A. Beck,et al.  Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. , 1985, The American journal of psychiatry.

[26]  E. sanders-Bush,et al.  Multiple serotonin receptors: regional distribution and effect of Raphe lesions. , 1981, European journal of pharmacology.

[27]  B. McEwen,et al.  Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. , 1986, Archives of general psychiatry.

[28]  F. Chaouloff,et al.  Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical 5-HT2A receptors. , 1997, European journal of pharmacology.

[29]  A. Weissman The Dysfunctional Attitude Scale: A Validation Study , 1979 .

[30]  K. Dobson,et al.  Cognitive assessment of depression: reliability and validity of three measures. , 1983, Journal of abnormal psychology.

[31]  C Crouzel,et al.  [18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. , 1988, European journal of pharmacology.

[32]  F. Artigas,et al.  The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain , 1996, Neuroscience Letters.

[33]  D. Kupfer,et al.  Pet imaging of serotonin 1A receptor binding in depression , 1999, Biological Psychiatry.

[34]  W M Grove,et al.  How does cognitive therapy work? Cognitive change and symptom change in cognitive therapy and pharmacotherapy for depression. , 1990, Journal of consulting and clinical psychology.

[35]  J. Mann,et al.  INCREASED SEROTONIN-2 BINDING SITES IN FRONTAL CORTEX OF SUICIDE VICTIMS , 1983, The Lancet.

[36]  S. Checkley,et al.  A Comparison of the Growth Hormone Responses to Clonidine and Apomorphine in the Same Patients with Endogenous Depression , 1984, British Journal of Psychiatry.

[37]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[38]  J. Simiand,et al.  Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[39]  A. Greenshaw,et al.  A behavioural and neurochemical analysis of chronic and selective monoamine oxidase inhibition , 2004, Psychopharmacology.

[40]  B. Mulsant,et al.  PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. , 1999, The American journal of psychiatry.

[41]  N. Alpert,et al.  Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. , 1996, The Journal of pharmacology and experimental therapeutics.

[42]  A. Beck Cognitive therapy and the emotional disorders: A. T. Beck , 1987, British Journal of Psychiatry.

[43]  J. Simiand,et al.  Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist. , 1993, European journal of pharmacology.

[44]  C. Katona,et al.  Brain 5-HT uptake sites, labelled with [3H]paroxetine, in antidepressant-free depressed suicides , 1990, Brain Research.

[45]  I. Ferrier,et al.  5HT2 receptor changes in major depression , 1990, Biological Psychiatry.

[46]  G. Aimard,et al.  [Study of Beck's hopelessness scale. Validation and factor analysis]. , 1992, L'Encephale.

[47]  C. McDougle,et al.  Tryptophan Depletion During Continuous CSF Sampling in Healthy Human Subjects , 1998, Neuropsychopharmacology.

[48]  P A Sargent,et al.  Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. , 2000, Archives of general psychiatry.

[49]  E. Pothos,et al.  d-fenfluramine, but not d-norfenfluramine, uses calcium to increase extracellular serotonin. , 1995, Life sciences.

[50]  E. Leibenluft,et al.  Dysfunctional Attitudes in Borderline Personality Disorder , 1991 .

[51]  V. Arango,et al.  A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. , 2000, Archives of general psychiatry.

[52]  M. Fava,et al.  Dysfunctional attitudes and poor problem solving skills predict hopelessness in major depression. , 1999, Journal of affective disorders.

[53]  J. Baron,et al.  Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  E. Robins,et al.  Some clinical considerations in the prevention of suicide based on a study of 134 successful suicides. , 1959, American journal of public health and the nation's health.

[55]  I. Miller,et al.  Characteristics of depressed patients with elevated levels of dysfunctional cognitions , 1988, Cognitive Therapy and Research.

[56]  J. Oliver,et al.  The Dysfunctional Attitude Scale: Psychometric properties and relation to depression in an unselected adult population , 1985, Cognitive Therapy and Research.

[57]  P. Liddle,et al.  Brain serotonin2 receptors in major depression: a positron emission tomography study. , 2000, Archives of general psychiatry.

[58]  Gregory M. Brown,et al.  Dose-response profiles of plasma growth hormone and vasopressin after clonidine challenge in man , 1990, Psychiatry Research.

[59]  G. Curzon,et al.  Depletion and repletion of cortical tissue and dialysate 5-HT after reserpine , 1994, Neuropharmacology.

[60]  D. Chuang,et al.  Characterization of Two [3H]Ketanserin Recognition Sites in Rat Striatum , 1987, Journal of neurochemistry.

[61]  M. Åsberg,et al.  "Serotonin depression"--a biochemical subgroup within the affective disorders? , 2003, Science.

[62]  C. Benkelfat,et al.  Relapse of depression after rapid depletion of tryptophan , 1997, The Lancet.

[63]  Bryan L Roth,et al.  Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists , 2001, Brain Research Bulletin.

[64]  K. Silk,et al.  Biological implications of childhood sexual abuse in borderline personality disorder. , 1997, Journal of personality disorders.

[65]  C. Stockmeier,et al.  In vivo regulation of the serotonin-2 receptor in rat brain. , 1986, Life sciences.

[66]  Ralph Myers,et al.  Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates , 1999, NeuroImage.

[67]  M. Åsberg,et al.  Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls , 1981, Psychiatry Research.

[68]  A. Simons,et al.  The process of change in cognitive therapy and pharmacotherapy for depression. Changes in mood and cognition. , 1984, Archives of general psychiatry.

[69]  A. Beck,et al.  Prediction of eventual suicide in psychiatric inpatients by clinical ratings of hopelessness. , 1989, Journal of consulting and clinical psychology.

[70]  C. Fischette,et al.  Effects of 5, 7-dihydroxytryptamine on serotonin1 and serotonin2 receptors throughout the rat central nervous system using quantitative autoradiography , 1987, Brain Research.

[71]  Stanley J. Watson,et al.  Serotonin transporter binding sites and mRNA levels in depressed persons committing suicide , 1997, Biological Psychiatry.

[72]  J. Leysen,et al.  5‐HT2 Receptors, Roles and Regulation , 1990, Annals of the New York Academy of Sciences.